TALEN

TALEN1-pink1

ID

ZDB-TALEN-170815-1

Name

TALEN1-pink1

Previous Names

None

Target

pink1 (1)

Target Sequence 1

5' - TCAGGCCTCAAACTGCC - 3'

Target Sequence 2

5' - TTCCCCCTCTGTTCACCC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
gi2	pink1

Expression

Gene expression in Wild Types + TALEN1-pink1

No data available

Phenotype

Phenotype resulting from TALEN1-pink1

No data available

Phenotype of all Fish created by or utilizing TALEN1-pink1

Phenotype	Fish	Conditions	Figures
whole organism ATP decreased amount, abnormal	pink1^gi2/gi2	chemical treatment by environment: rotenone	Fig. 3 from Zhang et al., 2017
thigmotaxis decreased occurrence, abnormal	pink1^gi2/gi2	chemical treatment by environment: antimycin A	Fig. S1 from Zhang et al., 2017
whole organism ATP decreased amount, ameliorated	pink1^gi2/gi2	chemical treatment by environment: rotenone, chemical treatment by environment: fluphenazine	Fig. 3 from Zhang et al., 2017
thigmotaxis decreased occurrence, abnormal	pink1^gi2/gi2	chemical treatment by environment: bafilomycin A1, chemical treatment by environment: piericidin A, chemical treatment by environment: trifluoperazine	Fig. 4 from Zhang et al., 2017
midbrain dopaminergic neuron decreased amount, ameliorated	pink1^gi2/gi2	chemical treatment by environment: trifluoperazine	Fig. 4 from Zhang et al., 2017
midbrain dopaminergic neuron Ab12-th labeling decreased amount, abnormal	pink1^gi2/gi2	control	Fig. 1 from Zhang et al., 2017
whole organism ATP decreased amount, ameliorated	pink1^gi2/gi2	chemical treatment by environment: trifluoperazine, chemical treatment by environment: rotenone	Fig. 3 from Zhang et al., 2017
midbrain dopaminergic neuron decreased amount, ameliorated	pink1^gi2/gi2	chemical treatment by environment: trifluoperazine, chemical treatment by environment: rotenone	Fig. 4 from Zhang et al., 2017
midbrain dopaminergic neuron decreased amount, abnormal	pink1^gi2/gi2	control	Fig. 2, Fig. 4 from Zhang et al., 2017
thigmotaxis decreased occurrence, abnormal	pink1^gi2/gi2	chemical treatment by environment: piericidin A	Fig. 4 from Zhang et al., 2017
midbrain dopaminergic neuron decreased amount, exacerbated	pink1^gi2/gi2	chemical treatment by environment: rotenone, chemical treatment by environment: bafilomycin A1, chemical treatment by environment: trifluoperazine	Fig. 4 from Zhang et al., 2017
whole organism ATP decreased amount, ameliorated	pink1^gi2/gi2	chemical treatment by environment: prochlorperazine, chemical treatment by environment: rotenone	Fig. 3 from Zhang et al., 2017
thigmotaxis decreased occurrence, abnormal	pink1^gi2/gi2	chemical treatment by environment: rotenone	Fig. 1 from Zhang et al., 2017
midbrain dopaminergic neuron decreased amount, exacerbated	pink1^gi2/gi2	chemical treatment by environment: rotenone	Fig. 2, Fig. 4 from Zhang et al., 2017
thigmotaxis decreased occurrence, ameliorated	pink1^gi2/gi2	chemical treatment by environment: piericidin A, chemical treatment by environment: trifluoperazine	Fig. 4 from Zhang et al., 2017
whole organism sqstm1 expression increased amount, abnormal	pink1^gi2/gi2	chemical treatment by environment: trifluoperazine, chemical treatment by environment: rotenone	Fig. 7 from Zhang et al., 2017
midbrain dopaminergic neuron Ab12-th labeling decreased amount, abnormal	pink1^gi2/gi2	chemical treatment by environment: rotenone	Fig. 1 from Zhang et al., 2017
thigmotaxis decreased occurrence, abnormal	pink1^gi2/+	chemical treatment by environment: rotenone	Fig. 1 from Zhang et al., 2017
muscle mitophagy increased occurrence, abnormal	pink1^gi2/gi2; zf3335Tg	chemical treatment by environment: dimethyloxalylglycine	Fig. 7 from Wrighton et al., 2021

Citations